|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 117.60 INR | -2.00% |
|
-5.92% | +63.58% |
| 05-21 | Dubai Investments says Globalpharma signs 7 strategic MoUs | RE |
| 05-20 | ZIM Laboratories Limited, Q4 2026 Earnings Call, May 20, 2026 |
Sales 2026 by Business Segment
Sales 2026 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
| Fiscal Period: March | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
Pharmaceutical Products | ||||||||||
Pharmaceuticals | 3.34B | 3.99B | 3.68B | 3.79B | 3.74B | |||||
Total Assets | 3.42B | 3.42B | 4.47B | 4.72B | 5.39B | |||||
Interest Expense | -71.69M | -49.7M | -58.82M | -94.72M | -121M | |||||
Income Tax Expense | 64.92M | 109M | 63.96M | 58.44M | 23.75M | |||||
CAPEX | -152M | -367M | -739M | -408M | -444M | |||||
EBT | 210M | 354M | 236M | 180M | 82.13M | |||||
D&A | 160M | 172M | 155M | 195M | 193M | |||||
Net Income | 146M | 244M | 172M | 122M | 58.38M |
Geographical Revenue Distribution History
| Fiscal Period: March | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
Outside India | 2.7B | 3.38B | 2.87B | 3.12B | 3.15B | |||||
Total Assets | 835M | 987M | 960M | 1.19B | 1.31B | |||||
CAPEX | -12.26M | -64.93M | -103M | -102M | -115M | |||||
India | 633M | 603M | 805M | 666M | 594M | |||||
Total Assets | 2.48B | 2.32B | 3.36B | 3.48B | 3.61B | |||||
CAPEX | -150M | -298M | -733M | -420M | -342M |
- Stock Market
- Stocks
- ZIMLAB Stock
- Financials ZIM Laboratories Limited
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
